A Study to Evaluate Intramuscular ASP7374

UMN Pharma

Status and phase

Completed

Phase 3

Conditions

Influenza

Vaccine

Treatments

Biological: ASP7374

Study type

Interventional

Funder types

Industry

Identifiers

7374-CL-0105

Details and patient eligibility

About

The purpose of this study is to evaluate safety and immunogenicity of intramuscular ASP7374 in adults ≥61 years of age.

Enrollment

55 patients

Sex

All

Ages

61+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy or medically stable, as judged on the basis of history and concurrent diseases.
Subject understands procedure of the protocol and is willing to comply with the protocol.
Written informed consent has been obtained.

Exclusion criteria

Scheduled to receive another vaccine during the study.
Received influenza HA vaccine within 180 days prior to screening.
Received or scheduled to receive a live vaccine within 28 days prior to vaccination with the study vaccine, and received or scheduled to receive an inactivated vaccine or a toxoid within 7 days prior to vaccination with the study vaccine.
Diagnosis of immune deficit in the past, has a family member (within the third degree of kinship) with a diagnosis of congenital immunodeficiency syndrome.
Received one of the following medications or treatment prior to vaccination with the study vaccine: Interferon formulation, Drugs which affect the immune system, corticosteroids, G-CSF, M-CSF, Human immunoglobulin products, Blood products, Blood transfusion
History of anaphylactic shock or an allergic reaction such as generalized eruption due to food or drug (including vaccines) allergies, fever ≥39.0°C within 2 days after the previous vaccination (influenza vaccine and others)
History of seizures, except for febrile seizures in childhood